Market outlook to 2032: future trends across the seven major markets
European Pharmaceutical Review
JANUARY 18, 2024
In its report on the insomnia market published last month, GlobalData expected that sales for DORAs, which offer a new mechanism of action for the condition, will continue to grow at a CAGR of 8.6 billion by 2023, driven by the launch of Merck’s Belsomra and Eisai’s lemborexant (E-2006). million in sales by 2032.
Let's personalize your content